文献速递围术期管理与 ERAS胃肠外科

减重手术与不手术对肥胖相关用药长期变化的影响

Temporal Changes in Obesity-Related Medication After Bariatric Surgery vs No Surgery for Obesity.
PubMed 文献 · JAMA Surg · 2023-01-01

这项基于瑞典(2005-2020)和芬兰(1995-2018)的人群队列研究比较了接受减重手术(胃旁路或袖状胃切除)的肥胖患者与5倍匹配对照者的长期用药轨迹。结果显示,减重手术与降脂药和降糖药使用的持久大幅减少相关,但心血管药物使用的减少仅为暂时性。

要点

  • 减重术后降脂药使用长期低于未手术组,15年时差距明显
  • 减重术后降糖药使用同样持久减少,而未手术组持续上升
  • 心血管药物使用的减少在术后2年明显,但15年时仅为暂时性

核心结论

  • 与不手术相比,减重手术与降脂药和降糖药使用的持久大幅减少相关,而心血管药物使用的减少仅为暂时性。

研究设计与样本

  • 基于瑞典(2005-2020)和芬兰(1995-2018)的人群队列研究。
  • 分析时间为2021年7月至2022年1月。

主要发现

  • 减重手术组降脂药使用比例从基线20.3%(95%CI 20.2%-20.5%)降至2年后12.9%(95%CI 12.7%-13.0%),15年后为17.6%(95%CI 13.3%-21.8%)。
  • 未手术组降脂药使用比例从基线21.0%(95%CI 20.9%-21.1%)升至15年后44.6%(95%CI 41.7%-47.5%)。
  • 减重手术组降糖药使用比例从基线27.7%(95%CI 27.6%-27.9%)降至2年后10.0%(95%CI 9.9%-10.2%),15年后为23.5%(95%CI 18.5%-28.5%)。
  • 未手术组降糖药使用比例从基线27.7%(95%CI 27.6%-27.7%)升至15年后54.2%(95%CI 51.0%-57.5%)。
  • 减重手术组心血管药物使用比例从基线60.2%(95%CI 60.0%-60.5%)降至2年后43.2%(95%CI 42.9%-43.4%),15年后升至74.6%(95%CI 65.8%-83.4%)。

临床怎么用

  • 围术期及长期随访中应关注减重术后降脂药和降糖药使用的持久下降,适时调整用药。
  • 对减重术后患者的心血管药物管理需长期监测,因该类用药减少可能仅为暂时性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Bariatric surgery can resolve hyperlipidemia, cardiovascular disease, and diabetes, but the long-term postoperative trajectories of medications for these conditions are unknown. OBJECTIVE: To clarify the long-term use of lipid-lowering, cardiovascular, and antidiabetic medication after bariatric surgery compared with no surgery for morbid obesity. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study took place in Sweden (2005-2020) and Finland (1995-2018) and included individuals diagnosed with obesity. Analysis took place between July 2021 and January 2022. EXPOSURES: Bariatric surgery (gastric bypass or sleeve gastrectomy) patients using lipid-lowering, cardiovascular, or antidiabetic medication were compared with 5 times as many control patients with an obesity diagnosis treated with no surgery, matched for country, age, sex, calendar year, and medication use. MAIN OUTCOMES AND MEASURES: Proportions with 95% CIs of lipid-lowering, cardiovascular, or antidiabetic medication. RESULTS: A total of 26 396 patients underwent bariatric surgery (with gastric bypass or sleeve gastrectomy) (17 521 [66.4%] women; median [IQR] age, 50 [43-56] years) and 131 980 matched control patients (87 605 [66.4%%] women; median [IQR] age, 50 [43-56] years) were included. The proportion of lipid-lowering medication after bariatric surgery decreased from 20.3% (95% CI, 20.2%-20.5%) at baseline to 12.9% (95% CI, 12.7%-13.0%) after 2 years and 17.6% (95% CI, 13.3%-21.8%) after 15 years, while it increased in the no surgery group from 21.0% (95% CI, 20.9%-21.1%) at baseline to 44.6% (95% CI, 41.7%-47.5%) after 15 years. Cardiovascular medications were used by 60.2% (95% CI, 60.0%-60.5%) of bariatric surgery patients at baseline, decreased to 43.2% (95% CI, 42.9%-43.4%) after 2 years, and increased to 74.6% (95% CI, 65.8%-83.4%) after 15 years, while it increased in the no surgery group from 54.4% (95% CI, 54.3%-54.5%) at baseline to 83.3% (95% CI, 79.3%-87.3%) after 15 years. Antidiabetic medications were used by 27.7% (95% CI, 27.6%-27.9%) in the bariatric surgery group at baseline, decreased to 10.0% (95% CI, 9.9%-10.2%) after 2 years, and increased to 23.5% (95% CI, 18.5%-28.5%) after 15 years, while it increased in the no surgery group from 27.7% (95% CI, 27.6%-27.7%) at baseline to 54.2% (95% CI, 51.0%-57.5%) after 15 years. CONCLUSIONS AND RELEVANCE: In this study, undergoing bariatric surgery was associated with a substantial and long-lasting reduction in the use of lipid-lowering and antidiabetic medications compared with no surgery for obesity, while for cardiovascular medications this reduction was only transient.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Kauppila JH, Markar S, Santoni G, et al. Temporal Changes in Obesity-Related Medication After Bariatric Surgery vs No Surgery for Obesity. JAMA Surg. 2023. PMID: 37223939. doi:10.1001/jamasurg.2023.0252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。